

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (FG-167) VUPANORSEN  
PRONUNCIATION vue" pa nor' sen  
THERAPEUTIC CLAIM Treatment of hyperlipidemia

CHEMICAL NAME

1. DNA, d([2'-O-(2-methoxyethyl)]rG-s<sup>p</sup>-[2'-O-(2-methoxyethyl)]rG-[2'-O-(2-methoxyethyl)]rA-[2'-O-(2-methoxyethyl)]m<sup>5</sup>rC-[2'-O-(2-methoxyethyl)]rA-T-s<sup>p</sup>-T-s<sup>p</sup>-G-s<sup>p</sup>-m<sup>5</sup>C-s<sup>p</sup>-m<sup>5</sup>C-s<sup>p</sup>-A-s<sup>p</sup>-G-s<sup>p</sup>-T-s<sup>p</sup>-A-s<sup>p</sup>-A-s<sup>p</sup>-[2'-O-(2-methoxyethyl)]m<sup>5</sup>rU-[2'-O-(2-methoxyethyl)]m<sup>5</sup>rC-[2'-O-(2-methoxyethyl)]rG-s<sup>p</sup>-[2'-O-(2-methoxyethyl)]m<sup>5</sup>rC-s<sup>p</sup>-[2'-O-(2-methoxyethyl)]rA), 5'-[26-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-14,14-bis[[[3-[[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]hexyl]amino]-3-oxopropoxy]methyl]-8,12,19-trioxo-16-oxa-7,13,20-triazahexacos-1-yl hydrogen phosphate]
2. *all-P-ambo-5'-O-[[[6-{5-[(tris{3-[6-(2-acetamido-2-deoxy-β-D-galactopyranosyloxy)hexylamino]-3-oxopropoxymethyl})methyl]amino-5-oxopentanamido}hexoxy]]phospho}-2'-O-(2-methoxyethyl)-P-thioguanlyl-(3'-O→5'-O)-2'-O-(2-methoxyethyl)guanylyl-(3'-O→5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O→5'-O)-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'-O→5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O→5'-O)-P-thiothymidylyl-(3'-O→5'-O)-P-thiothymidylyl-(3'-O→5'-O)-2'-deoxy-P-thioguanlyl-(3'-O→5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O→5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O→5'-O)-2'-deoxy-P-thioadenylyl-(3'-O→5'-O)-2'-deoxy-P-thioguanlyl-(3'-O→5'-O)-P-thiothymidylyl-(3'-O→5'-O)-2'-deoxy-P-thioadenylyl-(3'-O→5'-O)-2'-deoxy-P-thioadenylyl-(3'-O→5'-O)-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'-O→5'-O)-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'-O→5'-O)-2'-O-(2-methoxyethyl)-P-thioguanlyl-(3'-O→5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'-O→5'-O)-2'-O-(2-methoxyethyl)adenosine*

STRUCTURAL FORMULA

1 ggacattgcc agtaaucgca

MOLECULAR FORMULA C<sub>296</sub>H<sub>434</sub>N<sub>86</sub>O<sub>152</sub>P<sub>20</sub>S<sub>13</sub>

MOLECULAR WEIGHT 8665.5

TRADEMARK	None as yet
SPONSOR	Akcea Therapeutics
CODE DESIGNATION	ISIS 703802; AKCEA-ANGPTL3-L <sub>Rx</sub>
<u>CAS</u> REGISTRY NUMBER	2097587-62-5
UNII	A7YG62NHZ6
WHO NUMBER	11175

SCS